AVITA Medical Sees Q2 Commercial Revenue $14.3M-$15.3M; FY24 Commercial Revenue Expected To Be In The Lower End Of Previous Guidance Of $78.5M-$84.5M
AVITA Medical Sees Q2 Commercial Revenue $14.3M-$15.3M; FY24 Commercial Revenue Expected To Be In The Lower End Of Previous Guidance Of $78.5M-$84.5M
Financial Guidance
財務指導
- Commercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 million
- Commercial revenue for the full-year 2024 is expected to be in the lower end of our previously provided guidance range of $78.5 to $84.5 million, reflecting growth of approximately 57% at the lower end of the range over the full-year 2023
- Expect to achieve previously given guidance of cashflow break even and GAAP profitability no later than the third quarter of 2025
- 預計2024年第二季度的商業收入將在1430萬美元至1,530萬美元之間
- 預計2024年全年的商業收入將處於我們先前提供的7,850萬美元至8,450萬美元的指導區間的較低水平，反映出2023年全年該區間低端增長約57％
- 預計不遲於2025年第三季度實現先前給出的現金流、收支平衡和GAAP盈利能力指導。
"We acknowledge the significant cash utilization this quarter, however we remain confident in our financial stability and our ability to reach cashflow break even as guided," said David O'Toole, Chief Financial Officer of AVITA Medical. "It's important to note that the cash use was driven by several non-recurring items, including expenses incurred related to our distribution agreement with Stedical, totaling approximately $4.0 million for inventory purchases and other costs. Of this amount, approximately $3.1 million represents inventory that we will recover through future product sales, with gross sales in the range of $6 million."
AVITA Medical首席財務官戴維·奧圖爾表示：“我們承認本季度現金利用率很高，但我們對自己的財務穩定以及按照指導實現現金流收支平衡的能力仍然充滿信心。”“值得注意的是，現金使用是由幾個非經常性項目推動的，包括與我們與Stedical的分銷協議相關的費用，總額約爲400萬美元的庫存購買和其他成本。其中，大約310萬美元是我們將通過未來產品銷售回收的庫存，總銷售額在600萬美元之間。”
譯文內容由第三人軟體翻譯。